Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real‐life study
| Autor: | Julien Cassereau, C. Baron, D. Videt, Jean-Baptiste Noury, Armelle Magot, L. Michel, Yann Péréon, Steeve Genestet, A. Nadaj‐Pakleza, A. Dos Santos, Sandrine Wiertlewski |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Bradycardia
medicine.medical_specialty Cytopenia business.industry medicine.disease Gastroenterology Myasthenia gravis 03 medical and health sciences 0302 clinical medicine Neurology Refractory Internal medicine medicine Rituximab 030212 general & internal medicine Neurology (clinical) Repetitive nerve stimulation medicine.symptom Life study Adverse effect business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | European Journal of Neurology. 27:2277-2285 |
| ISSN: | 1468-1331 1351-5101 |
| DOI: | 10.1111/ene.14391 |
| Popis: | BACKGROUND AND PURPOSE Fifteen percent of patients with myasthenia gravis (MG) are refractory to conventional treatment. Case reports and a few studies show probable benefit of rituximab in these cases. Our objective was to assess the efficacy and the safety of rituximab in patients with MG, in a multicentric real-life study. METHOD Inclusion criteria were: age > 18 years; MG with anti-acetylcholine receptor (AChR) antibodies, anti-muscle-specific kinase (MuSk) antibodies or significant decrement after repetitive nerve stimulation; Myasthenia Gravis Foundation of America (MGFA) class >II; refractory or steroid-dependent MG; and treatment with rituximab. Efficacy was assessed at 6 months using the MGFA-post-intervention status (PIS) score, the myasthenic muscle score (MMS) and the number of patients receiving steroids |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text